Novartis

News

Novartis blocks generic to MS blockbuster Gilenya in US pate...

Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US for almost six years.

News

Novartis bags elusive US approval for cholesterol drug incli...

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Novartis adds gene therapy for blindness with Gyroscope buy

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect.

News

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.

News

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking

Patients

Patient engagement processes: the pharmaphorum podcast

This episode of the pharmaphorum podcast is the second in a limited series focused on patient engagement that’s being led by clinician, consultant and patient advocate, Mark Duman.

Novartis blocks generic to MS blockbuster Gilenya in US pate...

Novartis bags elusive US approval for cholesterol drug incli...

Novartis adds gene therapy for blindness with Gyroscope buy

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Patient engagement processes: the pharmaphorum podcast

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks